HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Davood Bashash Selected Research

NVP-BKM120

2/2022Synergistic effects of BKM120 and panobinostat on pre-B acute lymphoblastic cells: an emerging perspective for the simultaneous inhibition of PI3K and HDACs.
5/2020Anti-leukemic effect of PI3K inhibition on chronic myeloid leukemia (CML) cells: shedding new light on the mitigating effect of c-Myc and autophagy on BKM120 cytotoxicity.
1/2020PI3K Abrogation Using Pan-PI3K Inhibitor BKM120 Gives Rise to a Significant Anticancer Effect on AML-Derived KG-1 Cells by Inducing Apoptosis and G2/M Arrest
11/2019Inhibition of PI3K pathway using BKM120 intensified the chemo-sensitivity of breast cancer cells to arsenic trioxide (ATO).
1/2019Anticancer effect of pan-PI3K inhibitor on multiple myeloma cells: Shedding new light on the mechanisms involved in BKM120 resistance.
12/2018Inhibition of PI3K signaling pathway enhances the chemosensitivity of APL cells to ATO: Proposing novel therapeutic potential for BKM120.
10/2017Novel pan PI3K inhibitor-induced apoptosis in APL cells correlates with suppression of telomerase: An emerging mechanism of action of BKM120.
10/2016Inhibitor of pan class-I PI3K induces differentially apoptotic pathways in acute leukemia cells: Shedding new light on NVP-BKM120 mechanism of action.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Davood Bashash Research Topics

Disease

60Neoplasms (Cancer)
09/2022 - 02/2012
15Acute Promyelocytic Leukemia
01/2021 - 02/2012
13Leukemia
11/2021 - 10/2016
10Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
03/2022 - 03/2013
10Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Leukemia, Pre B Cell)
03/2022 - 10/2016
10Breast Neoplasms (Breast Cancer)
12/2021 - 10/2016
9COVID-19
08/2022 - 01/2020
5Hematologic Neoplasms (Hematological Malignancy)
09/2022 - 03/2019
5Inflammation (Inflammations)
10/2021 - 01/2020
4Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
11/2021 - 01/2017
3Carcinogenesis
07/2022 - 01/2020
3Ovarian Neoplasms (Ovarian Cancer)
10/2021 - 12/2019
3BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
05/2021 - 05/2020
3Neoplasm Metastasis (Metastasis)
12/2019 - 02/2012
2Glioblastoma (Glioblastoma Multiforme)
01/2022 - 01/2016
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2022 - 10/2021
2Multiple Myeloma
11/2021 - 01/2019
2Infections
01/2021 - 01/2021
2Rheumatoid Arthritis
01/2021 - 12/2020
2Carcinoma (Carcinomatosis)
01/2017 - 01/2017
1Thrombocytopenia (Thrombopenia)
08/2022
1Melanoma (Melanoma, Malignant)
01/2022
1Acute Lung Injury
01/2022
1Immune System Diseases (Immune Disorders)
01/2022
1Lymphoma (Lymphomas)
11/2021
1Neuroinflammatory Diseases
11/2021
1Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
10/2021
1Virus Diseases (Viral Diseases)
08/2021
1Lung Injury
08/2021
1Head and Neck Neoplasms (Head and Neck Cancer)
06/2021
1Urinary Bladder Neoplasms (Bladder Cancer)
04/2021
1Arthritis (Polyarthritis)
02/2021
1Squamous Cell Carcinoma of Head and Neck
01/2021

Drug/Important Bio-Agent (IBA)

19Arsenic Trioxide (Trisenox)FDA Link
01/2022 - 02/2012
10Pharmaceutical PreparationsIBA
04/2022 - 11/2016
10Biomarkers (Surrogate Marker)IBA
06/2021 - 10/2016
9Proteins (Proteins, Gene)FDA Link
05/2021 - 01/2017
8NVP-BKM120IBA
02/2022 - 10/2016
8Telomerase (Telomerase Reverse Transcriptase)IBA
03/2019 - 03/2013
6Toll-Like Receptor 4IBA
01/2021 - 06/2019
5Doxorubicin (Adriamycin)FDA LinkGeneric
03/2022 - 11/2016
5idelalisibIBA
02/2022 - 01/2017
5BIBR 1532IBA
09/2020 - 03/2013
4PanobinostatIBA
02/2022 - 01/2020
4MicroRNAs (MicroRNA)IBA
12/2021 - 02/2012
4Histone Deacetylases (Histone Deacetylase)IBA
11/2021 - 01/2020
4CytokinesIBA
06/2021 - 12/2019
4Vincristine (Oncovin)FDA LinkGeneric
03/2020 - 01/2019
4ethyl 6- (N- (2- chloro- 4- fluorophenyl)sulfamoyl)cyclohex- 1- ene- 1- carboxylateIBA
01/2020 - 06/2019
3Cyclin-Dependent Kinases (cdk Proteins)IBA
07/2022 - 01/2019
3Caspase 3 (Caspase-3)IBA
03/2022 - 07/2017
3EnzymesIBA
11/2021 - 01/2020
3Pioglitazone (Actos)FDA Link
11/2021 - 01/2020
3Histone Deacetylase InhibitorsIBA
11/2021 - 01/2020
3Messenger RNA (mRNA)IBA
10/2021 - 01/2018
3Tyrosine Kinase InhibitorsIBA
05/2021 - 05/2020
3Phosphatidylinositols (Phosphatidylinositol)IBA
01/2021 - 12/2018
3Aprepitant (Emend)FDA Link
10/2018 - 11/2016
3MelatoninIBA
01/2018 - 10/2016
2CyclinsIBA
07/2022 - 01/2019
2Annexin A5IBA
03/2022 - 01/2022
2Gentian Violet (Violet, Crystal)FDA Link
01/2022 - 09/2020
23- (4- methylphenylsulfonyl)- 2- propenenitrileIBA
01/2022 - 01/2018
2Immune Checkpoint InhibitorsIBA
12/2021 - 10/2021
2PPAR gammaIBA
11/2021 - 01/2021
2Insulin (Novolin)FDA Link
11/2021 - 09/2020
2Transcription Factors (Transcription Factor)IBA
10/2021 - 01/2020
2SurvivinIBA
04/2021 - 01/2018
2Toll-Like Receptors (Toll-Like Receptor)IBA
01/2021 - 01/2021
2carfilzomibIBA
01/2021 - 01/2019
24- (2,6- dichlorobenzoylamino)- 1H- pyrazole- 3- carboxylic acid piperidin-4-ylamideIBA
01/2020 - 01/2019
2ErbB Receptors (EGF Receptor)IBA
08/2019 - 01/2017
2dacomitinibIBA
08/2019 - 01/2017
2Hormones (Hormone)IBA
01/2019 - 01/2018
2Neurokinin-1 Receptors (Neurokinin 1 Receptor)IBA
10/2018 - 01/2018
2CaspasesIBA
01/2018 - 01/2017
1Chimeric Antigen ReceptorsIBA
09/2022
1COVID-19 VaccinesIBA
09/2022
1AntigensIBA
09/2022
1VaccinesIBA
09/2022
1Hemoglobins (Hemoglobin)IBA
08/2022
1L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
08/2022
1Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA
07/2022
1S63845IBA
03/2022
1Phosphoric Monoester Hydrolases (Phosphatases)IBA
01/2022
1Complement System Proteins (Complement)IBA
01/2022
1Dual-Specificity PhosphatasesIBA
01/2022
1Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA
11/2021
1Peroxisome Proliferator-Activated Receptors (PPAR)IBA
11/2021
1Interleukin-17 (Interleukin 17)IBA
10/2021
1Interleukin-10 (Interleukin 10)IBA
10/2021
1Antiviral Agents (Antivirals)IBA
06/2021
1Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA
01/2021
1Imatinib Mesylate (Gleevec)FDA Link
01/2021

Therapy/Procedure

31Therapeutics
09/2022 - 01/2016
5Immunotherapy
02/2022 - 01/2021
5Drug Therapy (Chemotherapy)
01/2022 - 01/2017
1Hematopoietic Stem Cell Transplantation
01/2022
1Molecular Targeted Therapy
01/2022
1Immunomodulation
08/2021